A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

DSpace/Manakin Repository

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
 
van Not, Olivier J; Wind, Thijs T; Ismail, Rawa K; Bhattacharya, Arkajyoti; Jalving, Mathilde; Blank, Christian U; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; Boers-Sonderen, Marye J; van den Eertwegh, Alfonsus J M; de Groot, Jan Willem B; Haanen, John B; Kapiteijn, Ellen; Bloem, Manja; Piersma, Djura; van Rijn, Rozemarijn S; Stevense-den Boer, Marion; van der Veldt, Astrid A M; Vreugdenhil, Gerard; Wouters, Michel W J M; Blokx, Willeke A M; Suijkerbuijk, Karijn P M; Fehrmann, Rudolf S N; Hospers, Geke A P
(2023) Cancers, volume 15, issue 11
(Article)
Abstract
The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: advanced melanoma, brain metastases, immunotherapy, survival tree, Oncology, Cancer Research, Journal Article
DOI: https://doi.org/10.3390/cancers15112922
ISSN: 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
Note: Funding Information: R.I. has no declarations of interest for this research however is employed at MSD since January 2022. A.v.d.E. has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, and Merck, has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera, and TEVA, has received travel expenses from MSD Oncology, Roche, Pfizer, and Sanofi, and has received speaker honoraria from BMS and Novartis. J.H. has advisory relationships with Aimm, Achilles Therapeutics, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, BioNTech, GSK, Immunocore, Ipsen, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, and Vaximm and has received research grants not related to this paper from Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics, and Novartis. All grants were paid to the institutions. M.J. has advisory relationships with AstraZeneca, Bristol Myers Squibb, Pierre Fabre, and GSK. All grants were paid to the institution. C.B. has received commercial research grants from Novartis, Bristol Myers Squibb, and NanoString, is a paid advisory board member for Bristol Myers Squibb, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, and Pierre Fabre, and holds ownership interests in Uniti Cars, Neon Therapeutics, and Forty Seven. M.A. has advisory board/consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, and Bayer. Research grants have been received from Merck-Pfizer, not related to current work and paid to the institute. J.d.G. has consultancy/advisory relationships with Bristol Myers Squibb, Pierre Fabre, Servier, MSD, and Novartis. G.H. has consultancy/advisory relationships with Amgen, Bristol Myers Squibb, Roche, MSD, Pfizer, Novartis, and Pierre Fabre and has received research grants unrelated to this paper from Bristol Myers Squibb and Seerave and were paid to the institution. E.K. has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, Lilly, and Bayer; these were paid to the institution. Furthermore, she received research grants not related to this paper from Bristol Myers Squibb, Delcath, Novartis, and Pierre Fabre. R.v.R. has advisory board/consultancy honoraria from Pfizer and an expert meeting fee from Roche. A.v.d.V. has consultancy relationships with Bristol Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, Eisai, and Merck (all paid to the institute). M.B.S. has consultancy/advisory relationships with Pierre Fabre, MSD, and Novartis. K.S. has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, and AbbVie and received honoraria from Novartis, MSD, and Roche. All remaining authors have declared no conflicts of interest. Publisher Copyright: © 2023 by the authors.
(Peer reviewed)